Physician profile
David P Gerard
NPI 1942312210
$1,599.09
in general payments reported to CMS, 2019-2025
22 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.69 · 2021: $93.92 · 2022: $165 · 2023: $253 · 2024: $541 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204 · Education: $78.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.87 |
| Education | $78.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $386.32 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $213.58 | 2019-2025 | |
| Abbvie INC. | $144.18 | 2019-2024 | |
| Gilead Sciences, INC. | $100.78 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $98.45 | 2022-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $93.94 | 2024-2025 | Voquezna |
| Genzyme Corporation | $82.83 | 2023 | |
| Novo Nordisk INC | $57.03 | 2025 | Wegovy |
| Ardelyx, INC. | $55.77 | 2023-2024 | Ibsrela |
| Celltrion USA INC. | $46.38 | 2024 | Zymfentra |
| Orphalan INC | $42.90 | 2025 | Cuvrior |
| Celgene Corporation | $34.32 | 2021-2023 | Zeposia |
| Mauna Kea Technologies, INC. | $33.94 | 2021-2025 | |
| Braintree Laboratories, INC. | $31.44 | 2019-2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $30.08 | 2025 | Iqirvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.96 | 2024 | Zepbound |
| Janssen Biotech, INC. | $24.40 | 2025 | Tremfya |
| Echosens North America, INC. | $23.44 | 2023 | Fibroscan |
| Azurity Pharmaceuticals, INC. | $19.45 | 2025 | Sutab |
| Amag Pharmaceuticals, INC. | $17.91 | 2021 | |
| Evoke Pharma, INC. | $17.21 | 2024 | |
| Intercept Pharmaceuticals, INC. | $16.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gerard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.